Lundbeck broadens phase III trial of Vyepti in children

Previous participants in Lundbeck trials are being brought together in a new phase III study that aims to investigate the long-term safety of use of migraine drug Vyepti in childhood.
Photo: Thomas Borberg
Photo: Thomas Borberg
by mikkel aabenhus hemmingsen, translated by catherine brett

Children and young people who have previously participated in clinical trials of migraine drug Vyepti have now been offered the chance to remain in treatment for a longer period.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading